Testing effectiveness (Phase 2)Study completedNCT02927769
What this trial is testing
Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Who this might be right for
Hodgkin Disease
Bristol-Myers Squibb 72